Keyword: Vedanta Biosciences
Vedanta Biosciences will advance its pipeline of microbiome-derived drugs, including a handful of assets currently in midstage trials.
Vedanta’s pact with J&J on microbiome therapies has moved to the clinical stage, triggering a $12 million milestone payment.
PureTech affiliate Vedanta Biosciences announced a partnership to create immune-boosting cancer therapies that capitalize on the gut microbiome.
Vedanta snagged the first major pharma microbiome deal with Johnson & Johnson and is slated to head into the clinic next year with the pharma and on its own, after rounding up a $50 million Series A in June.
Vedanta Biosciences has partnered with the NYU Langone Medical Center to develop microbiome-derived immunotherapies specifically for use paired with checkpoint inhibitors.
Vedanta Biosciences has raised $50 million from a clutch of big-name biotech backers to move multiple microbiome modulators into the clinic.